No Data
No Data
Bluebird Bio Works to Resolve Financial Reporting Delays
Express News | Bluebird bio Announces Receipt of Expected Notices From Nasdaq
Bluebird Bio Announces Receipt of Expected Notices From Nasdaq
J.P. Morgan Maintains Bluebird Bio(BLUE.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)
What 4 Analyst Ratings Have To Say About Bluebird Bio
No Data
Boxman : Maybe this is just a way to get the price a little lower im thinking .40 entry
IDKWTFIMDOING Boxman : Can I ask how you see .4? It just bounced off support the other day. It has slid down the bottom Bollinger for a bit now. SI is 16% with 3.93 days to cover at current volume.
It appears to be a loading zone right now. Your thoughts?
Boxman : For blue bird ?
Boxman IDKWTFIMDOING : This is a big pharma company look at the history, and it had lot of black rock involved so im expecting some fuckery
Boxman IDKWTFIMDOING : It’s a spin off of regeneron and 27bio i think, they have no csh that they are telling us about so I think. With some good news they’ll set a trap and pump it down to .40 cents and then when there. Or maybe it falls to 40 so they can get in at. Lower price. I don’t trust anything over .60
View more comments...